The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 18: 2525 - 2529

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.18.003

Clinical Advances

The pathogenesis and potential therapeutic targets of metaflammation in NAFLD

  • Chunyan NIU ,
  • Jiankang. HUANG
Expand
  • Department of Digestive Diseases，Lishui People′ s Hospital，Nanjing 211200，China

Received date: 2024-05-14

  Online published: 2024-09-30

Fold

Abstract

"Metaflammation，" proposed by Hotamisligil in 2006， refers to a chronic low-grade inflammation triggered by metabolic factors such as excessive nutrition and energy， persisting at subacute levels over an extended period. Immune cells infiltrate the inflammatory site， leading to enhanced expression or activity of various inflammatory molecules and subsequent inflammatory damage. Recent research on metabolic-related fatty liver disease has revealed that modern metaflammation plays a pivotal role in the pathogenesis of NAFLD. The associated inflammatory pathways offer promising prospects for the development of targeted drugs. This article provides an updated review on the advancements in metaflammation within NAFLD.

Key words： metaflammation; NAFLD; inflammatory molecules; inflammatory pathways; targeted drugs

Cite this article

Chunyan NIU , Jiankang. HUANG . The pathogenesis and potential therapeutic targets of metaflammation in NAFLD[J]. The Journal of Practical Medicine, 2024 , 40(18) : 2525 -2529 . DOI: 10.3969/j.issn.1006-5725.2024.18.003

References

1 PAIK J M， KABBARA K， EBERLY K E， et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults［J］. Hepatology， 2022，75（5）：1204-1217. doi:10.1002/hep.32228
2 HOTAMISLIGIL G S. Inflammation and metabolic disorders［J］. Nature， 2006，444（7121）：860-867.
3 牛春燕，赵向阳. 肝巨噬细胞靶向治疗脂肪性肝病及相关肝癌的机遇与挑战［J］. 临床肝胆病杂志， 2020，36（6）：1393-1397.
4 LEMMER I L， WILLEMSEN N， HILAL N， et al. A guide to understanding endoplasmic reticulum stress in metabolic disorders［J］. Mol Metab， 2021，47：101169.
5 SCH?FFLER A. Rolle der Metaflammation als systemische Manifestation bei Stoffwechselerkrankungen ［Role of metaflammation as a systemic manifestation of metabolic diseases］［J］. Inn Med （Heidelb）， 2023， 64（4）：313-322.
6 KING B C， BLOM A M. Complement in metabolic disease： metaflammation and a two-edged sword［J］. Semin Immunopathol， 2021， 43（6）：829-841.
7 MASTROCOLA R， ARAGNO M， ALLOATTI G， et al. Metaflammation： Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome［J］. Curr Med Chem， 2018，25（11）：1294-1310.
8 LIU Q， NIU C Y， ZHANG Q， et al. Amitriptyline inhibits NLRP3 inflammasome activation via the ASM/CE pathway in a cell model of NAFLD［J］. Biocell， 2024，48（5）：759-769.
9 BARNABEI L， LAPLANTINE E， MBONGO W， et al. NF-κB： At the Borders of Autoimmunity and Inflammation［J］. Front Immunol， 2021，12：716469. doi:10.3389/fimmu.2021.716469
10 HUANG X， YAO Y， HOU X， et al. Macrophage SCAP Contributes to Metaflammation and Lean NAFLD by Activating STING-NF-κB Signaling Pathway［J］. Cell Mol Gastroenterol Hepatol， 2022，14（1）：1-26.
11 XIONG P， ZHANG F， LIU F， et al. Metaflammation in glucolipid metabolic disorders： Pathogenesis and treatment［J］. Biomed Pharmacother， 2023， 161：114545.
12 FANG X， CAO J， TAO Z， et al. Hydroxytyrosol attenuates ethanol-induced liver injury by ameliorating steatosis， oxidative stress and hepatic inflammation by interfering STAT3/iNOS pathway［J］. Redox Rep， 2023，28（1）：2187564.
13 YAO J， ZHAO Y. Lp-PLA2 silencing ameliorates inflammation and autophagy in nonalcoholic steatohepatitis through inhibiting the JAK2/STAT3 pathway［J］. PeerJ， 2023，11：e15639.
14 LISCHKA J， SCHANZER A， DE GIER C， et al. Macrophage-associated markers of metaflammation are linked to metabolic dysfunction in pediatric obesity［J］. Cytokine， 2023，171：156372.
15 刘勤， 张强， 吴方雄， 等. 阿米替林对非酒精性脂肪性肝病细胞模型脂质沉积及生化代谢的影响［J］. 临床肝胆病杂志， 2021， 37（1）：99-104.
16 FERRIERE A， SANTA P， GARREAU A， et al. Self-Nucleic Acid Sensing： A Novel Crucial Pathway Involved in Obesity-Mediated Metaflammation and Metabolic Syndrome［J］. Front Immunol， 2021，11：624256.
17 ZHAO Q， LIU J， DENG H， et al. Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output［J］. Cell， 2020，183（1）：76-93.e22.
18 HAN S， ZHANG T， KUSUMANCHI P， et al. Long non-coding RNAs in liver diseases： Focusing on nonalcoholic fatty liver disease， alcohol-related liver disease， and cholestatic liver disease［J］. Clin Mol Hepatol， 2020， 26（4）：705-714.
19 ZENG Q， LIU CH， WU D， et al. LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease： A Systematic Review［J］. Biomolecules， 2023， 13（3）：560.
20 CALLEGARI I O M， ROCHA G Z， OLIVEIRA A G. Physical exercise， health， and disease treatment： The role of macrophages［J］. Front Physiol， 2023，14：1061353.
21 牛春燕， 陈跃， 宋用强. 初级保健和内分泌临床中非酒精性脂肪肝诊断和治疗的临床实践指南要点与解读 ［J］. 实用医学杂志， 2023， 39（3）： 267-273.
22 FRASER D A， WANG X， LUND J， et al. A structurally engineered fatty acid， icosabutate， suppresses liver inflammation and fibrosis in NASH［J］. J Hepatol， 2022，76（4）：800-811.
23 CHARLES-MESSANCE H， MITCHELSON K A J， DE MARCO CASTRO E， et al. Regulating metabolic inflammation by nutritional modulation［J］. J Allergy Clin Immunol， 2020，146（4）：706-720.
24 LI L L， WANG Y T， ZHU L， et al. Inulin with different degrees of polymerization protects against diet-induced endotoxemia and inflammation in association with gut microbiota regulation in mice［J］. Sci Rep， 2020， 10（1）： 978.
25 FANG J， YU C H， LI X J， et al. Gut dysbiosis in nonalcoholic fatty liver disease： Pathogenesis， diagnosis， and therapeutic implications［J］. Front Cell Infect Microbiol， 2022，12：997018.
26 TRINH B， DONATH M Y， L?UBLI H. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab［J］. Diabetes Care， 2019， 42（9）：e153-e154.
27 FEIJóO-BANDíN S， ARAGóN-HERRERA A， OTERO-SANTIAGO M， et al. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models［J］. Int J Mol Sci， 2022，23（10）：5634.
28 牛春燕，石永强，陈跃. 非酒精性脂肪性肝病的新兴靶向治疗药物研究进展［J］. 实用医学杂志， 2022， 38（11）： 1439-1442.
29 YU X， HAO M， LIU Y， et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy［J］. Eur J Pharmacol， 2019，864：172715.
30 LI J， CHEN C， ZHANG W， et al. Salsalate reverses metabolic disorders in a mouse model of non-alcoholic fatty liver disease through AMPK activation and caspase-6 activity inhibition［J］. Basic Clin Pharmacol Toxicol， 2021， 128（3）：394-409.
Options
Outlines

/

〈 〉